| Prev Close | 72.52 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 55.06 / 75.04 |
| Avg Volume | 5.44M |
| Exchange | NYSE |
| Shares Outstanding | 1.59B |
| Market Cap | 117.63B |
| EPS | 3.60 |
| P/E Ratio | 14.64 |
| Div & Yield | 2.56 (3.50%) |
Latest News
Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment
Remarkable data was released from Vertex's triple regiment combination trials.
All That Rises Is Not Tech: Top Takeaways From Jim Cramer's 'Off the Charts'
Tech companies aren't the only ones seeing their shares rise this year.
Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)
Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.
10 Sectors That Will Profit Big-Time From Oil's Crash
Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...
Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment
The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.
What Apple, Microsoft and Some of the World's Biggest Tech Companies Are Doing Now in Healthcare
Players include Apple, Google, Microsoft and Samsung.
Samsung Could Sell More Drugs
Samsung's Bioepis unit seeks final approval in Europe of a rheumatoid arthritis drug to compete with Humira.
Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)
Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.
AbbVie Receives CHMP Positive Opinion For MAVIRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)
- If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)(1)*
Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round
Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.
Dems Roast Trump for Leaving Medicare Out of Drug Price Order
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J
Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat
AbbVie Has Just Broken Out to the Upside and It Could Probably Keep Climbing Much Higher
AbbVie's June rally has now driven shares past the 2016 high.
New Data Presented At ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer A More Targeted Approach To Chronic Lymphocytic Leukemia (CLL) Treatment Than Chemotherapy Agent Chlorambucil In Treatment-Naive Patients
- IMBRUVICA effectively impacted cancerous cells while sparing non-cancerous white blood cells through one year of treatment
Long-Term IMBRUVICA® (ibrutinib) Efficacy And Safety Data At ASCO 2017 Show Sustained Survival Rates In Up To Four Years In Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those With High-Risk Disease
- Data show 59 percent progression free survival and 74 percent overall survival in CLL/SLL patients treated with IMBRUVICA, with high-risk patients trending to have the most favorable outcome[1]
S&P 500, Nasdaq Edge Higher as Crude Rebounds From Thursday Slump
Stocks are narrowly mixed on Friday, putting the S&P 500 and Nasdaq at risk of snapping a six-day winning streak.
Wall Street Weighs In on Athenahealth's Strategic Options
Elliott's previous successes in the healthcare space bode well for its chances at athena.
AbbVie Presents Pivotal Phase 3 Data On Investigational Treatment Elagolix At The World Congress On Endometriosis
- Primary and secondary efficacy and safety data to be presented from two pivotal Phase 3 studies evaluating the use of elagolix in endometriosis-associated pain
AbbVie Stock Lower on Humira Patent Ruling
The drug is responsible for more than 60% of AbbVie's top line.
AbbVie, Broadcom, Enbridge Energy Partners, Commercial Vehicle Group: 'Mad Money' Lightning Round
Jim Cramer is bullish on AbbVie, Broadcom, Enbridge Energy Partners, and Commercial Vehicle Group.
Industrials Are Stalling, Techs Are Roaring: Cramer's 'Mad Money' Recap (Monday 5/15/17)
Jim Cramer says investors are migrating toward sectors likely to have the biggest upside in the second half.
AbbVie Announces Positive Phase 2 Study Results For Upadacitinib (ABT-494), An Investigational JAK1-Selective Inhibitor, In Crohn's Disease
- Phase 2 study showed positive results in a moderately to severely active Crohn's disease patient population, the majority of whom had previously failed two or more biologics
